[
    [
        {
            "time": "",
            "original_text": "【招商策略】2020年3月陆股通持股分析 ——复盘本轮北上资金变动的四个阶段",
            "features": {
                "keywords": [
                    "招商策略",
                    "陆股通",
                    "北上资金",
                    "持股分析",
                    "四个阶段"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "金融",
                    "投资"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【招商策略】2020年3月陆股通持股分析 ——复盘本轮北上资金变动的四个阶段",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 4,
                "Headline_Structure": 6,
                "Source_Recency": 3
            }
        },
        {
            "time": "",
            "original_text": "沃森生物的“疫苗之王”首批14万支获批签发 打破辉瑞行业垄断",
            "features": {
                "keywords": [
                    "沃森生物",
                    "疫苗之王",
                    "首批14万支",
                    "获批签发",
                    "辉瑞",
                    "行业垄断"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "沃森生物的“疫苗之王”首批14万支获批签发 打破辉瑞行业垄断",
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        }
    ]
]